Quick Summary:
In the chronically evolving sphere of healthcare, the Global Brain Tumor Diagnosis and Treatment Market stands at a significant crossroad. Equipped with a current market valuation of US$1.4 Billion, forecasts project growth towards an auspicious US$2 Billion by 2030. Our comprehensive market analysis encapsulates the pivotal factors, trends, and potential challenges that primarily shape this dynamic market.
Insightful, evidence-based, and thoroughly credible, this report amplifies your understanding of the Primary Brain Tumor and Secondary Brain Tumor segments’ growth trajectory. Geographically, we examine the market evolution in key economies, including the U.S., China, Japan, Canada, and Germany. Furthermore, our analysis delves into the competitive landscape, featuring an in-depth analysis of 42 industry stalwarts, to provide you with a strategic advantage.
Take the decisive step towards informed decision-making, represent your organization with amplified market intelligence, and secure your position within the promising Global Brain Tumor Diagnosis and Treatment Market.
Global Brain Tumor Diagnosis and Treatment Market to Reach $2 Billion by 2030
The global market for Brain Tumor Diagnosis and Treatment estimated at US$1.4 Billion in the year 2022, is projected to reach a revised size of US$2 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2022-2030. Primary Brain Tumor, one of the segments analyzed in the report, is projected to record 4.2% CAGR and reach US$1.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Secondary Brain Tumor segment is readjusted to a revised 4.9% CAGR for the next 8-year period.The U.S. Market is Estimated at $385.9 Million, While China is Forecast to Grow at 7.8% CAGR
The Brain Tumor Diagnosis and Treatment market in the U.S. is estimated at US$385.9 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$455.1 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.7% and 4.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.Select Competitors (Total 42 Featured) -
- AstraZeneca PLC
- Carestream Health, Inc.
- GE Healthcare
- Hitachi Medical Corporation
- Merck & Co., Inc.
- Pfizer, Inc.
- Philips Healthcare
- Shimadzu Corporation
- Siemens Healthineers
- Toshiba Medical Systems Corporation
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Brain Tumor Diagnosis and Treatment?
What is the growth rate of the Global Market for Brain Tumor Diagnosis and Treatment?
What is the forecasted size of the Global Market for Brain Tumor Diagnosis and Treatment?
Who are the key companies in the Global Market for Brain Tumor Diagnosis and Treatment?
Report Attribute | Details |
---|---|
No. of Pages | 173 |
Published | December 2023 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 1.4 Billion |
Forecasted Market Value ( USD | $ 2 Billion |
Compound Annual Growth Rate | 4.6% |
Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AstraZeneca PLC
- Carestream Health, Inc.
- GE Healthcare
- Hitachi Medical Corporation
- Merck & Co., Inc.
- Pfizer, Inc.
- Philips Healthcare
- Shimadzu Corporation
- Siemens Healthineers
- Toshiba Medical Systems Corporation